WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584929

CAS#: 167887-97-0

Description: Olamufloxacin is a fluoroquinolone antibacterial.

Chemical Structure

CAS# 167887-97-0

Theoretical Analysis

MedKoo Cat#: 584929
Name: Olamufloxacin
CAS#: 167887-97-0
Chemical Formula: C20H23FN4O3
Exact Mass: 386.1754
Molecular Weight: 386.4274
Elemental Analysis: C, 62.16; H, 6.00; F, 4.92; N, 14.50; O, 12.42

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Olamufloxacin; HSR 903; HSR-903; HSR903

IUPAC/Chemical Name: 3-Quinolinecarboxylic acid, 5-amino-7-(7-amino-5-azaspiro(2,4)hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxo-, (S)-


InChi Code: InChI=1S/C20H23FN4O3/c1-9-16-13(18(26)11(19(27)28)6-25(16)10-2-3-10)15(23)14(21)17(9)24-7-12(22)20(8-24)4-5-20/h6,10,12H,2-5,7-8,22-23H2,1H3,(H,27,28)/t12-/m1/s1

SMILES Code: O=C(C1=CN(C2CC2)C3=C(C(N)=C(F)C(N(C[C@H]4N)CC54CC5)=C3C)C1=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 386.4274 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Sun J, Deguchi Y, Tauchi Y, He Z, Cheng G, Morimoto K. Distribution characteristics of orally administered olamufloxacin, a newly synthesized fluoroquinolone antibacterial, in lung epithelial lining fluid and alveolar macrophage in rats. Eur J Pharm Biopharm. 2006 Oct;64(2):238-45. Epub 2006 Jun 23. PubMed PMID: 16875808.

2: Sun J, Sakai S, Tauchi Y, Deguchi Y, Cheng G, Chen J, Morimoto K. Protonation equilibrium and lipophilicity of olamufloxacin (HSR-903), a newly synthesized fluoroquinolone antibacterial. Eur J Pharm Biopharm. 2003 Sep;56(2):223-9. PubMed PMID: 12957636.

3: Yoshizumi S, Takahashi Y, Murata M, Domon H, Furuya N, Ishii Y, Matsumoto T, Ohno A, Tateda K, Miyazaki S, Yamaguchi K. The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice. J Antimicrob Chemother. 2001 Jul;48(1):137-40. PubMed PMID: 11418525.

4: Jiraskova N. Olamufloxacin. Hokuriku Seiyaku. Curr Opin Investig Drugs. 2000 Sep;1(1):31-4. Review. PubMed PMID: 11249592.

5: Higa F, Arakaki N, Tateyama M, Koide M, Shinzato T, Kawakami K, Saito A. In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. J Antimicrob Chemother. 2003 Dec;52(6):920-4. Epub 2003 Nov 12. PubMed PMID: 14613952.

6: Chalyk BA, Butko MV, Yanshyna OO, Gavrilenko KS, Druzhenko TV, Mykhailiuk PK. Synthesis of Spirocyclic Pyrrolidines: Advanced Building Blocks for Drug Discovery. Chemistry. 2017 Nov 27;23(66):16782-16786. doi: 10.1002/chem.201702362. Epub 2017 Oct 10. PubMed PMID: 28800185.

7: Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000 Nov;89(11):1371-88. Review. PubMed PMID: 11015683.

8: Yoshizumi S, Takahashi Y, Watanabe Y, Okezaki E, Ishii Y, Tateda K. In vitro antibacterial activities of new fluoroquinolones against clinical isolates of haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC. Chemotherapy. 2004 Dec;50(6):265-75. Epub 2004 Dec 8. PubMed PMID: 15608441.

9: Takahashi Y, Masuda N, Otsuki M, Miki M, Nishino T. In vitro activity of HSR-903, a new quinolone. Antimicrob Agents Chemother. 1997 Jun;41(6):1326-30. PubMed PMID: 9174193; PubMed Central PMCID: PMC163909.

10: Yoshizumi S, Domon H, Miyazaki S, Yamaguchi K. In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. Antimicrob Agents Chemother. 1998 Apr;42(4):785-8. PubMed PMID: 9559783; PubMed Central PMCID: PMC105542.

11: Frean J, Klugman KP, Arntzen L, Bukofzer S. Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents. J Antimicrob Chemother. 2003 Aug;52(2):294-6. Epub 2003 Jul 15. PubMed PMID: 12865386.

12: Niki Y, Watanabe S, Tamada S, Yoshida K, Miyashita N, Nakajima M, Matsushima T, Sekino H, Matsuoka O. Effect of HSR-903, a new fluoroquinolone, on the concentration of theophylline in serum. Antimicrob Agents Chemother. 1999 Jun;43(6):1494-6. PubMed PMID: 10348779; PubMed Central PMCID: PMC89305.

13: Niki Y, Miyashita N, Kubota Y, Nakajima M, Matsushima T. In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic. Antimicrob Agents Chemother. 1997 Apr;41(4):857-9. PubMed PMID: 9087506; PubMed Central PMCID: PMC163811.

14: Tanaka M, Nakayama H, Haraoka M, Saika T, Kobayashi I, Naito S. Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics. Antimicrob Agents Chemother. 2000 Jan;44(1):192-5. PubMed PMID: 10602748; PubMed Central PMCID: PMC89653.

15: Murata M, Tamai I, Sai Y, Nagata O, Kato H, Tsuji A. Carrier-mediated lung distribution of HSR-903, a new quinolone antibacterial agent. J Pharmacol Exp Ther. 1999 Apr;289(1):79-84. PubMed PMID: 10086990.

16: Murata M, Tamai I, Sai Y, Nagata O, Kato H, Sugiyama Y, Tsuji A. Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. Drug Metab Dispos. 1998 Nov;26(11):1113-9. PubMed PMID: 9806954.

17: Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother. 1999 Dec;43(12):3001-4. PubMed PMID: 10582897; PubMed Central PMCID: PMC89602.

18: Murata M, Tamai I, Kato H, Nagata O, Tsuji A. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. J Pharmacol Exp Ther. 1999 Jul;290(1):51-7. PubMed PMID: 10381759.

19: Watanabe A, Tokue Y, Takahashi H, Kikuchi T, Kobayashi T, Gomi K, Fujimura S, Nukiwa T. In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections. Antimicrob Agents Chemother. 1999 Jul;43(7):1767-8. PubMed PMID: 10390240; PubMed Central PMCID: PMC89361.

20: Deguchi T, Yasuda M, Ishihara S, Takahashi Y, Okezaki E, Nagata O, Saito I, Kawada Y. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae with quinolone resistance-associated alterations in GyrA and ParC. J Antimicrob Chemother. 1997 Sep;40(3):437-9. PubMed PMID: 9338500.